The Division of Analytical Biosciences is part of the Leiden Academic Centre for Drug Research (LACDR) at the Faculty of Science of Leiden University. LACDR is a leading institute dedicated to world-class research and education in drug discovery and development. Leiden is the initiator and leader of the Netherlands Metabolomics Centre (NMC), a multidisciplinary public-private partnership between key academic players, clinical centers, research institutes, and industrial partners. Leiden has extensive experience in biomarker discovery with metabolomics in clinical and preclinical studies.
Prof. Dr. Thomas Hankemeier
Prof. Dr. Thomas Hankemeier is head of the Division for Analytical Biosciences at the Leiden Academic Centre for Drug Research (LACDR) of Leiden University.
His research is aimed at developing innovative analytical tools for metabolomics-driven systems biology in personalized health strategies.
As work package leader for WP4, Prof Hankemeier will be responsible for setting-up optimal metabolomic and morphological phenotyping platforms for clinical, in vitro, and in vivo Parkinson’s disease with mitochondrial dysfunction.
Dr. Amy Harms
Dr. Amy Harms is Lab Manager of the Metabolomics Facility at the Leiden Academic Centre for Drug Research (LACDR)
Please complete this sentence in relation to your work in the project.
She manages the metabolomics core facility for the Biomedical Metabolomics Facility Leiden. She has more than 25 years of experience in the field of mass spectrometry. She is particularly interested in instrumentation, data processing strategies, and quality control. Her expertise allows her to contribute to the experimental design, the actual collecting of data, evaluation and interpretation of data, and integration into the larger goals of the proposed projects.
She will be responsible for the metabolomics analysis of clinical samples in WP4.
Cornelius Willacey is a PhD candidate at the Leiden Academic Centre for Drug Research (LACDR).
He specialises in pharmacy and pharmacology, and will be expanding his knowledge in the study of metabolites related to mitochondrial dysfunction.
His work in the project will contribute to the optimisation and miniaturisation of the metabolomics phenotyping platform for Parkinson's disease in WP4.